TABLETING
AFFORDABLE PHARMA INSPECTION TECHNOLOGY M
ettler-Toledo Product Inspection used the Interpack 2023 event to showcase a wide range of
stand-alone and fully integrated automated smart product inspection systems. The technologies are all designed to help pharma manufacturers boost productivity, increase product safety, protect brand reputation and reduce recalls. The full suite
of technologies offers high-performing end- to-end inspection capabilities for liquid and solid pharma production lines. The key new technology launch
showcased at Interpack was X-ray Inspection - X2 Series, which offers high detection sensitivity performance and enhanced product quality control to help reduce product recalls. With two x-ray inspection systems currently in the X2 Series, the X12 and the X32, this future-proof technology is now accessible for all budgets. The series is designed for
the inspection of small and medium packages with a belt width of 300mm and 400mm. X-ray inspection solutions within the series are positioned to consistently deliver high detection sensitivity capabilities, protecting the safety and quality of pharma products. A key feature of the system is the ContamPlus
software, which enhances detection capabilities to identify a wide range of contaminants.
Alongside the new X2 Series, Mettler-
Toledo also showcased the X34C compact x-ray inspection system for pharma companies. X34C enables foreign body detection in small, packaged individually wrapped pharmaceutical products, such as blister packs and sachets at high production speeds. It facilitates cost-efficient inspection for customers immediately after flow- wrapping or sealing of individual products. Thanks to its compact design it is perfectly suited for use in production lines with very limited space. X34C supports belt speeds of up to 120m per minute. This makes it possible for the first time to match x-ray inspection to the high speeds of many form, fill and seal machines, such as those used for packaging individual pharma products.
For more information visit
www.mt.com
EXCIPIENT PROVES SUITABLE FOR CONTINUOUS MANUFACTURING B
eneo’s agglomerated pharmaceutical excipient galenIQ is suitable for continuous manufacturing of tablets, says a recently published comparative scientific study. The results show that compared to the reference polyol mannitol, galenIQ 721 exhibits a lower electrostatic charging propensity, as well as a significantly lower adhesion tendency to stainless steel surfaces. Moreover, the excipient is highly stable against segregation, thus further contributing to its excellent feeding performance. In the study, the authors compared
the feeding behaviour and process- induced tribo-charging (electrostatic charging) of isomalt and mannitol powders under process conditions with different magnitudes of shear and compression. During the trials, different feeding performance indicators, such as mass flow range and variability, end fill level and powder adhesion to the feeder surfaces, were selected for the benchmarking
purpose. The process-induced tribo- charging was measured, within the same feeding experiment, using a Faraday cup.
Both materials were comprehensively characterised for relevant powder properties. The results show that galenIQ 721 exhibits a lower tribo-charging propensity than the reference polyol, as well as a significantly lower adhesion tendency to stainless steel surfaces. Feeding performance of pure galenIQ 721 was found to be as effective as the feeding performance of spray-dried mannitol, with even less tendency to adhere to screw outlet and acquire charge during feeding.
Dr.Maj-Britt Cepok at Beneo comments:
“When it comes to the production of tablets, continuous manufacturing tableting is one of the most popular trends at the moment. It allows manufacturers to make cost savings and implement less complex production processes. To make the most of this potential, manufacturers need materials that are suitable for this type of production.”
For more information visit
www.beneo.com
www.scientistlive.com 49
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
